These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 2182057)

  • 21. Non-European traditional herbal medicines in Europe: a community herbal monograph perspective.
    Qu L; Zou W; Zhou Z; Zhang T; Greef J; Wang M
    J Ethnopharmacol; 2014 Oct; 156():107-14. PubMed ID: 25169214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unlicensed pharmaceutical preparations for clinical patient care: Ensuring safety.
    de Wilde S; de Jong MGH; Le Brun PPH; Guchelaar HJ; Schimmel KJM
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):3-8. PubMed ID: 29047193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The evolving horizon of drug registration--Europe and beyond.
    Currie WJ
    Eur J Clin Pharmacol; 1990; 39(5):453-6. PubMed ID: 2076736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
    Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
    Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works.
    Santoro A; Genov G; Spooner A; Raine J; Arlett P
    Drug Saf; 2017 Oct; 40(10):855-869. PubMed ID: 28735357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European union.
    Vlietinck A; Pieters L; Apers S
    Planta Med; 2009 Jun; 75(7):683-8. PubMed ID: 19204891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Europe and medicines: role of the EMEA].
    Sauer F
    Ann Pharm Fr; 2000 Jul; 58(4):278-85. PubMed ID: 10915977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Microbiological and biological methods of the European Pharmacopoeia. Relevant for each medicinal product].
    Norwig J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1158-68. PubMed ID: 25200487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The regulatory framework for complementary and alternative medicines in Europe].
    Knöss W; Stolte F; Reh K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):771-8. PubMed ID: 18584103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulatory affairs and biotechnology in Europe. II. The CPMP, "High Tech" and Multi-State procedures.
    Tryzelaar B
    Biotherapy; 1989; 1(3):179-96. PubMed ID: 2701848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Marketing of medicinal products in the European Community. The Mutual Recognition and Decentralised Procedures].
    Bachmann P
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):722-30. PubMed ID: 18560780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Experimental testing of centrally authorised medicinal products. The CAP programme].
    Giess S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1169-72. PubMed ID: 25159224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Veterinary pharmacovigilance. Part 1. The legal basis in the European Union.
    Woodward KN
    J Vet Pharmacol Ther; 2005 Apr; 28(2):131-47. PubMed ID: 15842304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Main characteristics of the new authorisation procedure for clinical trials with medicinal products according to regulation (EU) no 536/2014 and the cooperation between the member states].
    Sudhop T; Riedel C; Krafft H
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2023 Jan; 66(1):3-11. PubMed ID: 36478279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulatory environment for allergen-specific immunotherapy.
    Kaul S; May S; Lüttkopf D; Vieths S
    Allergy; 2011 Jun; 66(6):753-64. PubMed ID: 21288251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of community herbal monographs to facilitate registrations and authorisations of herbal medicinal products in the European Union 2004-2012.
    Peschel W
    J Ethnopharmacol; 2014 Dec; 158 Pt B():471-86. PubMed ID: 25043780
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Three years of paediatric regulation in the European Union.
    Olski TM; Lampus SF; Gherarducci G; Saint Raymond A
    Eur J Clin Pharmacol; 2011 Mar; 67(3):245-52. PubMed ID: 21286912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. European Medicines Evaluation Agency and the new licensing arrangements.
    Drug Ther Bull; 1994 Dec; 32(12):89-90. PubMed ID: 7635013
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Should Anthroposophic Medicinal Products Be Regulated in Europe?
    Michaux G
    Eur J Health Law; 2017 Mar; 24(1):46-66. PubMed ID: 29210253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Marketing authorization of veterinary medicinal products in Poland.
    Sztabińska-Koncka H; Lewicki J
    Regul Toxicol Pharmacol; 1997 Aug; 26(1 Pt 1):129-33. PubMed ID: 9339489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.